Travere Therapeutics names new R&D head ahead of 2027 retirement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as Big Tech earnings rekindle AI spending worries; oil hits $100
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits new 40-year high versus yen, euro lower after ECB decision
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
June 16, 2026 4:30 PM EDTWilliam Rote, Ph.D., chief research officer plans to retire in early 2027
Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the Companys research organization
SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Companys chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the... More
